The Alzheimer’s disease drug development landscape

por van Bokhoven, Pieter, de Wilde, Arno, Vermunt, Lisa, Leferink, Prisca S., Heetveld, Sasja, Cummings, Jeffrey, Scheltens, Philip, Vijverberg, Everard G. B.
Publicado 2021

Therapy Trial Design in Vanishing White Matter: An Expert Consortium Opinion

por van der Knaap, Marjo S., Bonkowsky, Joshua L., Vanderver, Adeline, Schiffmann, Raphael, Krägeloh-Mann, Ingeborg, Bertini, Enrico, Bernard, Genevieve, Fatemi, Seyed Ali, Wolf, Nicole I., Saunier-Vivar, Elise, Rauner, Robert, Dekker, Hanka, van Bokhoven, Pieter, van de Ven, Peter, Leferink, Prisca S.
Publicado 2022

Core protocol development for phase 2/3 clinical trials in the leukodystrophy vanishing white matter: a consensus statement by the VWM consortium and patient advocates

por Schoenmakers, Daphne H., Leferink, Prisca S., Vanderver, Adeline, Bonkowsky, Joshua L., Krägeloh-Mann, Ingeborg, Bernard, Geneviève, Bertini, Enrico, Fatemi, Ali, Fogel, Brent L., Wolf, Nicole I., Skwirut, Donna, Buck, Allyson, Holberg, Brett, Saunier-Vivar, Elise F., Rauner, Robert, Dekker, Hanka, van Bokhoven, Pieter, Stellingwerff, Menno D., Berkhof, Johannes, van der Knaap, Marjo S.
Publicado 2023